



ASX ANNOUNCEMENT

ASX:RSH

28 July 2022

## Successful Integration of wheezo® into Michigan Children's Hospital Ready for first Patient Intake

RespiRI Limited (ASX:RSH) ("RespiRI" or the "Company"), an eHealth SaaS Company supporting respiratory health management, is pleased to announce that Access Telehealth and RespiRI have successfully run a systems integration program with Michigan Children's Hospital to ensure RPM (Remote Patient Monitoring) systems and reimbursement services integrate appropriately. This integration covers RespiRI patient Apps and devices (wheezo®) as well as the RespiRI Health portal that manages the respiratory health data and Access unique proprietary RPM management platform, Remotli, that manages RPM services provision allowing doctors to monitor patients and then use this tracked data to claim reimbursement for the services.

To support this system integration program the RespiRI team developed and released Application Programming Interface (API) functionality allowing the RespiRI health portal to integrate seamlessly with Remotli and capture key data required for RPM reimbursement codes to be processed by payors. Data included is wheeze rate which are the physiological parameter required to qualify for the relevant RPM CPT (Current Procedural Terminology) code reimbursement.

The wheezo® ecosystem comprises the device, App and healthcare portal that together qualify for RPM reimbursement. The system provides physicians with objective physiological data and self-reported data from the real world in real time, the former a requirement for RPM reimbursement. Data captured includes breath recordings, wheeze rates and other factors which may trigger exacerbations such as, environmental information; air quality, pollution, pollen, medication usage and other symptoms and triggers the patient is experiencing. Currently physicians rely on patients' recall of these factors, which is communicated on questioning during a consultation, a process known to be less than adequate. wheezo® provides greater real time objective detail around the questions already being asked thus providing doctors with a clearer picture around a patient's respiratory condition making it easier for them to determine if it is deteriorating and act accordingly to avoid an exacerbation and a potential hospitalisation, which benefits the patients and reduces the financial burden for the payor.

This integration also allows for RespiRI data collected through customer interfaces to be sent across to Access systems, that provides the correct reporting of RPM patient data points, to facilitate reimbursement processes in the US.

This is a one-time investment that will reduce integration time with new Access engaged healthcare provider customers.

Access Telehealth is now undertaking system integration work with healthcare customer Electronic Medical Record (EMR), the critical patient records system that healthcare professionals, physicians included, use to record longitudinal healthcare data which is used to better manage the patient's condition over time. Introduction of additional systems into hospitals are major barriers to adoption of new services and products so this seamless option removes this barrier for wheezo® and Remotli for Michigan and future customers allowing for a simple reporting function that will enable better patient management and easier reimbursement claims to be made.

Marjan Mikel, RespiRI CEO said, "This is a further significant milestone for RespiRI, as this integration with our partner's Access Remotli system helps remove one of the barriers to customer adoption of wheezo® and simplifies the processing of RPM reimbursement, both of which should streamline the onboarding of future customers."

RespiRI looks forward to announcing the commence of first patient intakes at Michigan Children's hospital in the coming weeks and reimbursement using RPM codes in the US, the first Australia company device/system to be used to do so.

- ENDS -

*This ASX announcement has been authorised for release by the Board of Directors of Respi Limited.*

For further information, investors and media please contact:

**Mr Marjan Mikel**

CEO & Managing Director

Respi Limited

P: +61 408 462 873

E: [marjan@respi.co](mailto:marjan@respi.co)

**Mr Nicholas Smedley**

Executive Chairman

Respi Limited

P: +61 447 074 160

E: [nicholas@respi.co](mailto:nicholas@respi.co)

™ wheezo® is a trademark of Respi Limited.

---

## About Respi Limited

Respi is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respi's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respi's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respi Limited's operations are based in Melbourne, Australia.

For additional information about Respi and its products, please visit [www.respi.co](http://www.respi.co)

## About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respi current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respi only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.